Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: J07BB02

Flucelvax Tetra(A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022, CVR-167) A/Massachusetts/18/2022 (H3N2)-like strain (A/Sydney/1304/2022, wild type) B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type))

Influenza, Human

Marketing Authorisation Holder: Seqirus Netherlands B.V.

EMA Authorisation: 12/12/2018

INN: influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Indication

Prophylaxis of influenza in adults and children from 2 years of age. Flucelvax Tetra should be used in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Flucelvax Tetra — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Flucelvax TetraCreate Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.